Before undertaking the first trial in Indonesia the software was already learning from the input of adult coughs in its development phase.
Even back in 2012 when the initial more simple paper concerning the differentiation between wet and dry coughs was published, plenty of adult data was being recorded.
http://www.ncbi.nlm.nih.gov/pubmed/23366593
To save childrens lives and meet the consequent huge need for a paediatric solution, paediatric trials ran first with backing by Bill and Melinda Gates. Thus the algorithym has been given more exposure to paediatric coughs and has improved as a result. However the overall underlying smartness and astounding sophistication of the software requires only tweeking to deliver similar results in adults.
Consequently I think interim adult results will be good and improving as the machine learning advances.
As the need to advance the USA adult trials as an input to the FDA process is pressing, i would not be surprised if the Impending announcement was not a double barrell announcement covering that as well.
If not, I will be happy with good adult results Wednesday followed by improved overall market sentiment following the Brexit result and the second SP booster rocket announcement re the USA trial a few days later.
Fox
